Abstract
The efficacy and safety of tacrolimus- and cyclosporine-based immunosuppressive regimens were compared in a prospectively defined subgroup of kidney transplant recipients from the European, open, multicentre, 2 : 1 randomised, parallel group study. Patients were stratified as high risk for immunological events if they had a panel-reactive antibodies grade greater than 80 % and/or a previous transplant functional for less than 1 year. The primary efficacy variables evaluated were the incidence of acute rejection, steroid usage and patient and graft survival. Safety was assessed based on adverse events and laboratory evaluations. At 1 year, the tacrolimus group (n = 22) had a lower incidence of biopsy-proven acute rejection (31.8 %) and a higher graft survival (86.0 %) than the 11 patients in the cyclosporine group (54.5 % and 72.0 %, respectively). The frequencies of adverse events were similar between the two groups. The tacrolimus regimen appears more beneficial for high risk patients than cyclosporine.
Similar content being viewed by others
Author information
Authors and Affiliations
About this article
Cite this article
Hauser, I., Neumayer, HN., Mayer, A. et al. Tacrolimus and cyclosporine efficacy in high-risk kidney transplantation . Transpl Int 11 (Suppl 1), S73–S77 (1998). https://doi.org/10.1007/PL00014036
Issue Date:
DOI: https://doi.org/10.1007/PL00014036